J 2023

Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

ILARIA, Del Principe Maria, Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL et. al.

Základní údaje

Originální název

Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

Autoři

ILARIA, Del Principe Maria (garant), Danila SEIDEL, Marianna CRISCUOLO, Michelina DARGENIO, Zdeněk RÁČIL (203 Česká republika, domácí), Monica PIEDIMONTE, Francesco MARCHESI, Gianpaolo NADALI, Philipp KOEHLER, Nicola FRACCHIOLLA, Chiara CATTANEO, Nikolai KLIMKO, Angelica SPOLZINO, Deniz Yilmaz KARAPINAR, Hayati DEMIRASLAN, Rafael F DUARTE, Judit DEMETER, Marta STANZANI, Lorella Maria Antonia MELILLO, Claudia Maria BASILICO, Simone CESARO, Giovangiacinto PATERNO, Catello CALIFANO, Mario DELIA, Elisa BUZZATTI, Alessandro BUSCA, Oliver A CORNELY, Livio PAGANO, Nael ALAKEL, Valentina Arsi ARSENIJEVI'C, Vincent CAMUS, Iker FALCES-ROMERO, Levy ITZHAK, Michal KOUBA (203 Česká republika), Rodrigo MARTINO, Petr SEDLACEK (203 Česká republika) a Barbora WEINBERGEROVÁ (203 Česká republika, domácí)

Vydání

Mycoses, Hoboken, Wiley-Blackwell, 2023, 0933-7407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 4.900 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130241

Organizační jednotka

Lékařská fakulta

UT WoS

000855011600001

Klíčová slova anglicky

antifungal treatment; Candidemia; fungal infection; Geotrichum; Magnusiomyces; Saprochaete

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 4. 10. 2024 08:54, Mgr. Tereza Miškechová

Anotace

V originále

Background Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2-78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p < .0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p = .001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396-5.204, p = .003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151-4.376, p = .018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102-7.601, p < .001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192-5.222, p = .015). Conclusions Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.